Human hepatic cell line 5: In-vitro model for hepatic immunobiology.

BACKGROUND

Hepatocellular carcinoma (HCC) remains a major global health burden, partly due to the lack of physiologically relevant in vitro models that accurately recapitulate early host-virus interactions and immune responses. Human Hepatocyte Line 5 (HHL-5) is an immortalized hepatocyte cell line that retains key liver-specific functions. This study aimed to characterize the phenotypic, genetic, and metabolic features of HHL-5 cells and evaluate their suitability as a non-cancerous hepatic model, in comparison with the HCC cell line HepG2.

METHODS AND

RESULTS

Morphological and phenotypic assessment of cells showed smaller cell and nuclear areas and slower proliferation with markedly longer doubling time of HHL-5 cells than HepG2 cells. Genomic analyses using whole-exome sequencing revealed enrichment of immune-related pathways in HHL-5 cells, including antigen processing and presentation, whereas HepG2 cells showed predominance of DNA replication pathways. Metabolomic profiling of cells by nuclear magnetic resonance spectroscopy showed hepatocyte-like oxidative profiles of HHL-5 cells, in contrast to the glycolytic phenotypes of HepG2 cells. Moreover, Western blotting for selected proteins showed reduced expression of oncogenic and stress-response markers, including c-Myc, pSTAT3, pNrf2, and select cytochrome P450 enzymes.

CONCLUSION

Our findings support HHL-5 cells as a robust non-cancerous in vitro model for investigating liver diseases, viral infection, and early events in hepatocarcinogenesis.

CLINICAL TRIAL REGISTRATION: Not applicable.